Evidence map›Paper›PMID 28704582›Full record

ArticleNephrology (Carlton, Vic.)2018

Autosomal dominant form of type IV collagen nephropathy exists among patients with hereditary nephritis difficult to diagnose clinicopathologically.

Aya Imafuku, Kandai Nozu, Naoki Sawa, Eiko Hasegawa, Rikako Hiramatsu, Masahiro Kawada, Junichi Hoshino, Kiho Tanaka, Yasuo Ishii, Kenmei Takaichi and 4 more

Abstract read
In one paragraph

Article in Nephrology (Carlton, Vic.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Kidney biopsy guidebook 2020 in Japan.Clinical and experimental nephrology · 2021
    Guideline
  2. Article
  3. Article
  4. Article
  5. Pathological diagnosis of Alport syndrome.Kidney research and clinical practice · 2025
    Article
  6. Article
  7. Constructing networks for comparison of collagen types.Journal of integrative bioinformatics · 2024
    Article
  8. Article
  9. A Deeper Insight intoMolecular syndromology · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Identification of a novel pathogenicBiomedical reports · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aya ImafukuNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Kandai NozuDepartment of Pediatrics, Kobe University, Kobe, Japan.
Naoki SawaNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Eiko HasegawaNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Rikako HiramatsuNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Masahiro KawadaNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Junichi HoshinoNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Kiho TanakaNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Yasuo IshiiNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Kenmei TakaichiNephrology Center, Toranomon Hospital, Minato-ku, Japan.
Takeshi FujiiDepartment of Pathology, Toranomon Hospital, Minato-ku, Japan.
Kenichi OhashiDepartment of Pathology, Toranomon Hospital, Minato-ku, Japan.
Kazumoto IijimaDepartment of Pediatrics, Kobe University, Kobe, Japan.
Yoshifumi UbaraNephrology Center, Toranomon Hospital, Minato-ku, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimType IV collagen nephropathies include Alport Syndrome and thin basement membrane nephropathy (TBMN), which are caused by mutations in COL4A3/A4/A5 genes. Recently, reports of patients with heterozygous mutations in COL4A3/A4 have been increasing. The clinical course of these patients has a wide variety, and they are diagnosed as TBMN, autosomal dominant Alport syndrome (ADAS), or familial focal segmental glomerular sclerosis. However, diagnosis, frequency and clinicopathological manifestation of them remains unclear. We tested COL4A3/A4/A5 genes in patients with hereditary nephritis that was difficult to diagnose clinicopathologically, and investigated who should undergo such testing.

methodsWe performed immunostaining for α5 chain of type IV collagen [α5 (IV)] in 27 patients from 21 families who fitted the following criteria: (i) haematuria and proteinuria (± renal dysfunction); (ii) family history of haematuria, proteinuria, and/or renal dysfunction (autosomal dominant inheritance); (iii) no specific glomerulonephritis; and (iv) thinning, splitting, or lamellation of the glomerular basement membrane (GBM) on electron microscopy. Then we performed genetic testing in 19 patients from 16 families who showed normal α5 (IV) patterns. We conducted a retrospective analysis of their clinicopathological findings.

resultsAmong 16 families, 69% were detected heterozygous mutations in COL4A3/A4, suggesting the diagnosis of TBMN/ADAS. Twenty-one percent of patients developed end stage renal disease. All patients showed thinning of GBM, which was accompanied by splitting or lamellation in seven patients.

conclusionA considerable fraction of patients with hereditary nephritis that is difficult to diagnose clinicopathologically have TBMN/ADAS. It is important to recognize TBMN/ADAS and perform genetic testing in appropriate patients.

Indexed as

MutationAdultAgedAutoantigensBiopsyCollagen Type IVDisease ProgressionDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHematuriaHeredityHeterozygoteHumansKidneyKidney Failure, ChronicAutoantigensCOL4A4 protein, humanCOL4A5 protein, humanCollagen Type IVtype IV collagen alpha3 chainautosomal dominant Alport syndromeCOL4A3COL4A4thin basement membrane nephropathytype IV collagen α5 chain

Identifiers

PMID28704582
PMCPMC6767408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.